FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

O Ek

Research Profile

Living Beings

Chemicals & Drugs

Procedures

Disorders

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Y Messinger; Gregory H Reaman; O Ek; fatih uckun
Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
fatih uckun; Barbara Waurzyniak; Harland Sather; Martha G Sensel; LM Chelstrom; James B Nachman; Paul S Gaynon; Bruce C Bostrom; O Ek; MB Sarquis; Peter G Steinherz; Gregory H Reaman
Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.
O Ek; Paul S Gaynon; T Zeren; LM Chelstrom; DE Myers; fatih uckun
Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of O Ek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

1999: Y Messinger; Gregory H Reaman; O Ek; fatih uckun
Evaluation of temozolomide in a SCID mouse model of human B-cell precursor leukemia.
Leukemia & lymphoma 1999;33(3-4):289-93.
1999: fatih uckun; Barbara Waurzyniak; Harland Sather; Martha G Sensel; LM Chelstrom; James B Nachman; Paul S Gaynon; Bruce C Bostrom; O Ek; MB Sarquis; Peter G Steinherz; Gregory H Reaman
Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.
Leukemia & lymphoma 1999;32(5-6):475-87.
1998: O Ek; Paul S Gaynon; T Zeren; LM Chelstrom; DE Myers; fatih uckun
Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase.
Leukemia & lymphoma 1998;31(1-2):143-9.
1998: fatih uckun; Harland Sather; Barbara Waurzyniak; Martha G Sensel; LM Chelstrom; O Ek; MB Sarquis; James B Nachman; Bruce C Bostrom; Gregory H Reaman; Paul S Gaynon
Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study.
Leukemia & lymphoma 1998;30(5-6):503-14.
1998: O Ek; Y Yanishevski; T Zeren; Barbara Waurzyniak; R Gunther; LM Chelstrom; M Chandan-Langlie; E Schneider; DE Myers; W Evans; fatih uckun
In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
Leukemia & lymphoma 1998;30(3-4):389-94.
1998: O Ek; Barbara Waurzyniak; DE Myers; fatih uckun
Antitumor activity of TP3(anti-p80)-pokeweed antiviral protein immunotoxin in hamster cheek pouch and severe combined immunodeficient mouse xenograft models of human osteosarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(7):1641-7.
1998: fatih uckun; Rama Krishna Narla; T Zeren; Y Yanishevski; DE Myers; Barbara Waurzyniak; O Ek; E Schneider; Y Messinger; LM Chelstrom; R Gunther; W Evans
In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(5):1125-34.
1998: O Ek; Gregory H Reaman; D L Crankshaw; LM Chelstrom; DE Myers; fatih uckun
Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.
Leukemia & lymphoma 1998;28(5-6):509-14.
1998: Y Messinger; Y Yanishevski; O Ek; T Zeren; Barbara Waurzyniak; R Gunther; LM Chelstrom; M Chandan-Langlie; E Schneider; DE Myers; W Evans; fatih uckun
In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):165-70.
1997: J P Perentesis; R Gunther; Barbara Waurzyniak; Y Yanishevski; DE Myers; O Ek; Y Messinger; Y Shao; LM Chelstrom; E Schneider; William Evans; fatih uckun
In vivo biotherapy of HL-60 myeloid leukemia with a genetically engineered recombinant fusion toxin directed against the human granulocyte macrophage colony-stimulating factor receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2217-27.
1997: Barbara Waurzyniak; E A Schneider; N Tumer; Y Yanishevski; R Gunther; LM Chelstrom; H Wendorf; DE Myers; JD Irvin; Y Messinger; O Ek; T Zeren; MC Langlie; William Evans; fatih uckun
In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):881-90.
1997: fatih uckun; Z Yang; Harland Sather; Peter G Steinherz; James B Nachman; Bruce C Bostrom; L Crotty; MB Sarquis; O Ek; T Zeren; DG Tubergen; Gregory Reaman; Paul S Gaynon
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Blood 1997;89(10):3769-77.
1997: fatih uckun; Y Yanishevski; N Tumer; Barbara Waurzyniak; Y Messinger; LM Chelstrom; Elizabeth Lisowski; O Ek; T Zeren; H Wendorf; MC Langlie; JD Irvin; DE Myers; G B Fuller; W Evans; R Gunther
Pharmacokinetic features, immunogenicity, and toxicity of B43(anti-CD19)-pokeweed antiviral protein immunotoxin in cynomolgus monkeys.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):325-37.
1996: Y Messinger; Y Yanishevski; V I Avramis; O Ek; LM Chelstrom; R Gunther; DE Myers; JD Irvin; W Evans; fatih uckun
Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(9):1533-42.